danirixin   Click here for help

GtoPdb Ligand ID: 8500

Synonyms: GSK-1325756B | GSK1325756 | GSK1325756B
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Danirixin (GSK-1325756B) is being developed as a clinically efficacious antagonist of the CXCR2 chemokine receptor [2].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 4
Rotatable bonds 6
Topological polar surface area 115.91
Molecular weight 441.09
XLogP 4.68
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES O=C(Nc1cccc(c1C)F)Nc1ccc(c(c1O)S(=O)(=O)C1CCCNC1)Cl
Isomeric SMILES O=C(Nc1cccc(c1C)F)Nc1ccc(c(c1O)S(=O)(=O)[C@H]1CCCNC1)Cl
InChI InChI=1S/C19H21ClFN3O4S/c1-11-14(21)5-2-6-15(11)23-19(26)24-16-8-7-13(20)18(17(16)25)29(27,28)12-4-3-9-22-10-12/h2,5-8,12,22,25H,3-4,9-10H2,1H3,(H2,23,24,26)/t12-/m0/s1
No information available.
Summary of Clinical Use Click here for help
Danirixin is being evaluated in Phase 2 clinical trials as a potential anti-inflammatory treatment for the neutrophil-mediated airway inflammation associated with chronic obstructive pulmonary disease (COPD) [1]. Click here to link to ClinicalTrials.gov's full list of danirixin trials.